Pasar al contenido principal

NEUROTOXICIDAD INDUCIDA POR MECLORETAMINA, MECANISMOS MOLECULARES DE NEUROTOXICIDAD Y ABORDAJE TERAPEUTICO CON MELATONINA

PID2022-140164OB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Pharmacological evaluation of non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury

  • Valencia, Inés
  • Pastor-Martínez, Andrea
  • Decouty-Pérez, Céline
  • López-Rodriguez, Ana Belén
  • Álvarez-Rubal, María
  • Ramos Alonso, Eva
  • Calzaferri, Francesco
  • Zamorano-Fernández, Jorge
  • Giner-García, Javier
  • Palpán-Flores, Alexis J
  • Rodriguez-Dominguez, Victor
  • Rodríguez de Cía, Javier
  • Hernández-García, Borja J
  • Romero Martínez, Manuel Alejandro
  • De Los Rios, Cristobal
  • Egea, Javier
Background and purpose: Traumatic brain injury (TBI) is considered to be a leadingcause of mortality and disability worldwide. After TBI, innate immunity is rapidly acti-vated in response to damage-associated molecular patterns, such as ATP release,recognised by P2X7 receptors. The P2X7-NLRP3 inflammasome axis has been identi-fied as one of the main players in neuroinflammation. This study aimed to validateP2X7 receptors as therapeutic target for traumatic brain injury. Experimental approach: P2X7 receptors were studied by genetic and pharmacologi-cal approaches. Six non-nucleotide purine derivatives were evaluated as P2X7 antag-onists. Compounds that prevented LPS + ATP-induced IL-1β release from primaryglial cultures were investigated in the closed-head injury TBI model in vivo in malemice. Finally, we evaluated soluble (s)P2X7 receptor plasmatic levels in a cohort ofTBI patients. Key results: P2rx7 / mice showed an exaggerated inflammatory response 24 hpost-TBI compared to control mice. However, animals treated with the selective P2X7 antagonist JNJ-47965567 (30 mg kg 1 i.p.) 30 min post-TBI showed improvedneurological and inflammatory parameters. The purine derivative ITH15004 was themost potent compound reducing IL-1β production in vitro. When administered in vivo30 min post-TBI, ITH15004 (1 mg kg 1 i.p.) improved both neuro-behavioural andinflammatory markers at 24 h. In TBI patients, we showed a tendency towardsincrease in circulating sP2X7 receptor levels at 24 and 72 h post-TBI. Conclusions and implications: These results highlight the importance of P2X7 recep-tors in the acute phase of TBI and present ITH15004 as a promising pharmacologicaltool to counteract P2X7 receptor-dependent neuroinflammation in vivo.